Abstract:Abstract Inflammasomes are multi-protein signalling scaffolds that assemble in response to invasive pathogens and sterile danger signals to activate inflammatory caspases (1/4/5/11), which trigger inflammatory death (pyroptosis) and processing and release of pro-inflammatory cytokines 1,2 . Inflammasome activation contributes to many human diseases, including inflammatory bowel disease, gout, type II diabetes, cardiovascular disease, Alzheimer’s disease, and sepsis, the often fatal response to systemic infection 3–6 . The recent identification of the pore-forming protein gasdermin D (GSDMD) as the final pyroptosis executioner downstream of inflammasome activation presents an attractive drug target for these diseases 7–11 . Here we show that disulfiram, a drug used to treat alcohol addiction 12 , and Bay 11-7082, a previously identified NF-κB inhibitor 13 , potently inhibit GSDMD pore formation in liposomes and inflammasome-mediated pyroptosis and IL-1β secretion in human and mouse cells. Moreover, disulfiram, administered at a clinically well-tolerated dose, inhibits LPS-induced septic death and IL-1β secretion in mice. Both compounds covalently modify a conserved Cys (Cys191 in human and Cys192 in mouse GSDMD) that is critical for pore formation 8,14 . Inflammatory caspases employ Cys active sites, and many previously identified inhibitors of inflammatory mediators, including those against NLRP3 and NF-κB, covalently modify reactive cysteine residues 15 . Since NLRP3 and noncanonical inflammasome activation are amplified by cellular oxidative stress 16–22 , these redox-sensitive reactive cysteine residues may regulate inflammation endogenously, and compounds that covalently modify reactive cysteines may inhibit inflammation by acting at multiple steps. Indeed, both disulfiram and Bay 11-7082 also directly inhibit inflammatory caspases and pleiotropically suppress multiple processes in inflammation triggered by both canonical and noncanonical inflammasomes, including priming, puncta formation and caspase activation. Hence, cysteine-reactive compounds, despite their lack of specificity, may be attractive agents for reducing inflammation.

A small molecule inhibitor of caspase-1 inhibits NLRP3 inflammasome activation and pyroptosis to alleviate gouty inflammation

Sennoside A is a novel inhibitor targeting caspase-1

Fused Bicyclic Caspase‐1 Inhibitors Assembled by Copper‐Free Strain‐Promoted Alkyne–Azide Cycloaddition (SPAAC)

Discovery of a Covalent Inhibitor of Pro-Caspase-1 Zymogen Blocking NLRP3 Inflammasome Activation and Pyroptosis

Coptisine from Coptis chinensis blocks NLRP3 inflammasome activation by inhibiting caspase-1

Identification of pyroptosis inhibitors that target a reactive cysteine in gasdermin D

The Inhibitor Effect of RKIP on Inflammasome Activation and Inflammasome-Dependent Diseases

Identification of D359-0396 as a novel inhibitor of the activation of NLRP3 inflammasome

A novel NLRP3 inhibitor as a therapeutic agent against monosodium urate-induced gout

Scaffold hopping-driven optimization for the identification of NLRP3 inhibitors as potential gout therapeutics

Loganin Alleviates Gout Inflammation by Suppressing NLRP3 Inflammasome Activation and Mitochondrial Damage

Small molecule inhibitor binds to NOD-like receptor family pyrin domain containing 3 and prevents inflammasome activation

Identification of a selective and direct NLRP3 inhibitor to treat inflammatory disorders

Discovery of a novel pyroptosis inhibitor acting though modulating glutathionylation to suppress NLRP3-related signal pathway

Polysaccharide extract from Isatidis Radix inhibits multiple inflammasomes activation and alleviate gouty arthritis

Caspase-11 Mediates Neutrophil Chemotaxis and Extracellular Trap Formation During Acute Gouty Arthritis Through Alteration of Cofilin Phosphorylation

Mechanistic and therapeutic insights into the function of NLRP3 inflammasome in sterile arthritis

Small molecule inhibitor binds to NLRP3 and prevents inflammasome activation

A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases

The Angiotensin II Receptor Neprilysin Inhibitor LCZ696 Inhibits the NLRP3 Inflammasome By Reducing Mitochondrial Dysfunction in Macrophages and Alleviates Dextran Sulfate Sodium-induced Colitis in a Mouse Model

AA467197 Controls the Hyperactivation of the NLRP3 Inflammasome During Infection